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Abstract  
Background: Benzodiazepine and z-hypnotic prescribing has slowly decreased over the past 20 years, however long-term chronic 
prescribing still occurs and is at odds with prescribing guidance. 
Objectives: To identify the pattern of benzodiazepine and z-hypnotic prescribing in psychiatric inpatients at discharge and 12 months 
post-discharge. 
Methods: Retrospective observational longitudinal cohort study of patients admitted to two adult psychiatric wards between June and 
November 2012 (inclusive) who were discharged with a prescription for a benzodiazepine or z-hypnotic drug. Routinely collected 
prescription data available from NHS Scotland Prescribing Information System was used to identify and follow community prescribing 
of benzodiazepine and z-hypnotics for a 12 month period post-discharge. Data were entered in Excel® and further analysed using SPSS 
23. Ethical approval was not required for this service evaluation however Caldicott Guardian approval was sought and granted. 
Results: Eighty patients were admitted during the study period however only those patients with a single admission were included for 
analysis (n=74). Thirty per cent (22/74) of patients were prescribed a benzodiazepine or z-hypnotics at discharge; 14 of whom received 
‘long-term’ benzodiazepine and z-hypnotics i.e. continued use over the 12 month period. Seven patients received a combination of 
anxiolytics and hypnotics (e.g., diazepam plus temazepam or zopiclone). Long-term use was associated with a non-significant increase 
in median benzodiazepine or z-hypnotic dose, expressed as diazepam equivalents. 
Conclusions: One in three patients were prescribed a benzodiazepine or z-hypnotics at discharge with 1 in 5 receiving continuous long-
term treatment (prescriptions) for 12 months post-discharge. As chronic long-term B-Z prescribing and use still remains an issue, 
future strategies using routine patient-level prescribing data may support prescribers to review and minimise inappropriate long-term 
prescribing. 
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INTRODUCTION 
Benzodiazepine and z-hypnotic (B-Z) prescribing remains an 
issue across different care settings in North America, 
Australasia and Europe.1-3 Whilst there has been some 
reduction in the use of specific benzodiazepines, it appears 
to be at the expense of z-hypnotics, whose usage has 
increased.4 Much of the B-Z prescribing results in long-term 
chronic use1,2 which is contrary to good practice, guidance, 
and terms of license.5 B-Zs demonstrate marginal benefits 
for short-term relief of insomnia and some anxiety 
disorders6 which are traits common in most psychiatric 
disorders and so may warrant short-term or ‘as required’ 
use in acute settings. However, issues with tolerance, 
dependence and adverse effects including cognitive 
impairment, depression and paradoxical effects i.e. 
disinhibition, anxiety and impulsivity, can limit their 
usefulness.7 More recently, studies have reported 
increased mortality associated with B-Z use in various 
populations including those with psychiatric illness.8,9 
Information regarding B-Z prescribing upon discharge from 
inpatient psychiatric services is limited, although a few 
studies have reported that 36%, 37% and 50% of patients in 
New Zealand10 and the UK11,12 received B-Zs on discharge. 
More importantly, information is lacking regarding their 
prescribing post-discharge which may contribute to 
potentially inappropriate long-term prescribing in primary 
care. At a practical level, routine patient-level prescribing 
information required to follow a patient’s journey from 
hospital to community care is often lacking or incomplete 
in most health care systems. However, recent 
developments in Scotland in the collection and processing 
of routine patient-level primary care prescription 
dispensing data can now make this possible.13 This paper 
reports on a study which set out to identify the pattern of 
B-Z prescribing in psychiatric inpatients at discharge and 12 
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months post-discharge using routine patient-level 
prescribing and dispensing information.  
 
METHODS 
Ethical opinion was sought from the West of Scotland 
Research Ethics Service on the use of anonymised patient-
level data for the study. The advice received was that the 
study was considered to be service evaluation and hence 
did not require research ethics approval. Nevertheless, 
Caldicott Guardian approval was sought and granted by the 
NHS Greater Glasgow and Clyde Prescription Data 
Governance Group. 
A retrospective observational longitudinal cohort study 
design was applied. All patients admitted between June 
and November 2012, to two acute adult wards in the same 
psychiatric hospital, in the southwest region of the health 
board area were eligible for inclusion. Individual patient-
level data including: Community Health Index (CHI) 
number; age; gender; residential postcode to allow 
mapping of Scottish Index of Multiple Deprivation (SIMD) 
codes14; primary psychiatric diagnosis and admission status 
(informal or detained) were collected using a standardised 
data collection form. Patients with multiple admissions 
during the study period were excluded, as it was assumed 
these individuals were ‘more unwell/complicated’ and so 
any B-Z prescribed would not necessarily be representative 
of ‘routine practice’. 
In Scotland, healthcare is delivered by a tax funded 
National Health Service (NHS) and service users are 
assigned a CHI number. The CHI number acts as a unique 
identifier containing details of gender and date of birth.15 
The CHI number enables linkage to other national datasets 
which use the CHI number as their point of reference such 
as the national Prescribing Information System (PIS). The 
PIS contains information pertaining to all NHS prescriptions 
that have been dispensed in the community i.e. primary 
care.13 The overwhelming majority of which are prescribed 
by the patient’s general practitioner (GP), with a minority 
of prescriptions being written by non-medical prescribers 
(e.g. nurses and pharmacists), Out of Hours and speciality 
outpatient services and dispensed in community. The CHI 
number was used to identify patients who had received a 
prescription, in primary care, for a B-Zs during within 12 
months after discharge. The prescriptions included the 
patients CHI number and medication details: drug name, 
dosage form, strength, quantity dispensed, dosage 
instructions and date dispensed. 
Patient-level admission data and B-Z prescribing data were 
matched for the 12 months following discharge. Details of 
any B-Z dispensed at months 1 to 12 post-discharge 
including the name of the medication and the total daily 
dose were collected from PIS. Where dosage instructions 
were unavailable or ambiguous e.g. ‘as directed’ or ‘as 
required’, the average daily dose was estimated by dividing 
the total prescription dose by 28 days e.g. 14 temazepam 
10mg tablets (one as required) is 140mg/28 and would be 
recorded as a total daily dose of 5mg temazepam. As the 
majority of ‘as required’ and ‘as directed’ prescriptions 
were being dispensed monthly (e.g. zopiclone 7.5 mg 
tablets, 14 tablets, dispensed each month) and all regular 
prescriptions were supplied as 28 day prescriptions. 
To enable comparison of individual patient-level total daily 
doses at various times post-discharge, diazepam dose 
equivalents were calculated for the different B-Zs in line 
with previous guidance.16,17 Since most clinical guidelines 
and product licenses’ recommend restricting B-Z use to 2-4 
weeks5,6, long-term or inappropriate use was defined as 
‘receiving the medication for more than 4 weeks’. All data 
was anonymised prior to analysis. 
Data were entered in Excel and further analysed using SPSS 
v.23. Where appropriate, due to small cell sizes containing 
data counts <5, data were aggregated into ‘quarters’ for 
the 12 months post-discharge and were defined as: quarter 
1=month 1, 2 and 3, quarter 2=month 4, 5 and 6, etc. 
Where appropriate the Chi-square test or Mann-Whtney U 
test were used. Since the diazepam dose equivalents did 
not exhibit normal distribution, the Mann-Whitney U test 
was used to assess statistical difference between discharge 
doses and quarter 4 doses for all patients prescribed B-Zs.  
 
RESULTS  
Eighty patients were admitted during the study period, six 
of whom had multiple admissions and were thus excluded. 
The remaining 74 patients had a mean age of 40 years 
(range 18-77 years), 45 of whom (61%) were male with just 
over half (54%, n=40), according to the SIMD score, living in 
the 20% most deprived areas of Scotland. The most 
Table 1.Patient characteristics and demographics at discharge 
Patient sample n=74 B-Z prescribed n=22 (30%) B-Z not prescribed n=52 (70%)  
Gender    
Male           n=45 (%) 14 (64) 31 (60)  
Female       n=29 (%) 8  (36) 21 (40) chi-sq=0, df 1, p=1 
Median age years (range) 39 (26 to 62) 41 (18 to 77) Mann-Whitney U test p=0.511 
SIMD most deprived quintile (%) 12 (55) 52 (54) chi-sq =0.04, df 1, p=0.814 
Primary Psychiatric diagnosis    
Schizophrenia F20 7 18  
Mood disorder F30                                5 11  
Personality disorder F60 5 9 chi-sq =0.4, df 3, p=0.940 
Other: anxiety disorder, substance misuse, 
unknown 
5 14  
Admission status (%)    
   Informal   15 (68) 36 (69) chi-sq =0.03, df 1, p=0.862 
   Detained   7 (32) 16 (31)  
B-Z: Benzodiazepine or z-hypnotic.  Primary diagnosis grouped as per International Statistical Classification of Diseases and Related Health Problems 
10
th
 (ICD-10) Revision coding.
37
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common primary diagnosis was schizophrenia (n=25), 
followed by mood disorder (n=16), personality disorder 
(n=14), substance misuse (n=10) and anxiety disorder (n=7). 
Fourteen patients (19%) had multiple psychiatric co-
morbidities. Twenty-three patients (31%) were detained 
under Mental Health Act legislation on admission.  
Twenty-two patients (30%) were prescribed B-Z medication 
at discharge, five (7%) of whom received a combination of 
an anxiolytic and a hypnotic, e.g. diazepam plus 
temazepam or zopiclone, with males more commonly 
prescribed B-Zs (Odds Ratio 1.19, 95% CI 0.42 to 3.32). No 
significant differences in demographics were found 
between patients prescribed B-Zs and those not prescribed 
B-Zs at discharge (Table 1). The most commonly prescribed 
B-Zs were diazepam (n=11), zopiclone (n=8) and 
nitrazepam (n=3), with z-hypnotics more commonly 
prescribed than benzodiazepine-hypnotics. The median 
total daily dose expressed as diazepam equivalents was 
8mg (range 2.5mg to 50mg). Four patients, not discharged 
on B-Zs, started treatment within three months of 
discharge and remained on long-term treatment.  
B-Z prescribing for 12 months post-discharge 
Of the 22 patients discharged on B-Zs, six patients did not 
receive any further B-Zs prescriptions. Of the remaining 16 
patients (73%, 9 males and 7 females) who continued to 
receive repeat B-Z prescriptions post-discharge, 14 
individuals received ‘long-term’ treatment including 9 
patients receiving B-Zs continuously for 12 months; 3 
patients for 12 months with a single 4 week break in their 
supply, 1 patient for 10 months and another for 7 months. 
Only two patients received less than a 4 weeks supply post-
discharge. Three patients who were not originally 
discharged on B-Zs started and remained on long-term 
treatment: two for 12 months and one for 6 months 
continuously. 
Seven of the 16 patients were dispensed diazepam in 
combination with either nitrazepam, temazepam or a z-
hypnotic. Four of these individuals were prescribed these 
as ‘regular’ doses with the remainder using them on an ‘as 
required’ basis. Another 9 patients from the original cohort 
were found to have started a B-Z within the 12 months 
post-discharge period. Five of whom received short-term 
irregular treatment but 4 people received regular (long-
term) prescriptions of a single B-Zs. 
For all 25 patients who received B-Zs in the 12 months 
post-discharge, 275 B-Z prescriptions had been dispensed. 
The most frequent was diazepam (n=123, 45%, median 
total daily dose of 15mg, range 2mg to 50mg), followed by 
zopiclone (n=46, 17%, 7.5mg, 3.75mg to 15mg), nitrazepam 
(n=39, 14%, 10mg, 2.5mg to 20mg), zolpidem (n=28, 10%, 
10mg, 5mg to 10mg), temazepam (n=21, 8%, 20mg, 20mg 
to 60mg) and lorazepam/lormetazepam (n=18, 7%). The 
most common primary diagnosis amongst this cohort was 
schizophrenia (n=7), personality disorder (n=5) and mood 
disorders (n=5). The remainder were diagnosed with either 
an anxiety disorder, substance misuse or had an ‘unknown’ 
diagnosis. 
 B-Z long-term use 
Of the 14 patients discharged on B-Zs who subsequently 
received long-term regular prescriptions there was a 
statistically non-significant (Mann-Whitney U test, p=0.519) 
increase in median doses (expressed as diazepam 
equivalents) from 10mg at discharge to 15.8mg at 12 
months, Figure 1. For all patients (n=18) who received long-
Figure 1, Box plot of total daily doses (expressed as diazepam equivalents) for  patients prescribed Benzodiazepines or  
z-hypnotics at discharged and long-trem. 
Quarter 4, n=13 patients as one patient did not receive Benzodiazepines after 7 months of continuous treatment. Mann-
Whitney U test p=0.519 discharge versus quarter 4. 
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term B-Zs including those not prescribed at discharged, the 
most common primary diagnoses were schizophrenia (33%) 
followed by depression (22%) and personality disorder 
(22%). While the median dose for this group increased from 
10mg at discharge to 14.6mg at 12 months, Figure 2.  
 
DISCUSSION 
 One in three patients in this cohort were prescribed B-Zs at 
discharge. This is comparable to other studies10,12, but 
significantly lower than a previous UK study.11 One in five 
patients were also found to receive continuous, long-term, 
B-Zs prescriptions 12 months post-discharge. Most 
clinicians are aware of the problems associated with 
chronic B-Z use, and that courses should be limited to a 
maximum of 2-4 weeks5, stopping or reducing chronic 
prescribing in this instance may be more challenging. This 
may be partly due to patient or carer expectations of 
continuing treatment, or GPs having reservations in 
reducing or stopping B-Zs as they were initiated by 
specialist mental health services. GPs may also lack training 
or the psychiatrists support in managing the reduction and 
withdrawal of long-term B-Zs.18  
B-Z tolerance can develop quickly, particularly if there is 
dose escalation, and our study is the first to our knowledge 
to demonstrate small escalations in median doses over 
time. One factor acknowledged by others as contributing to 
dose escalation is concomitant use of 2 or more B-Zs. This 
was observed in a small proportion of our patients and was 
higher than that reported amongst a Spanish sample.19 
Diazepam was the most commonly prescribed B-Z, with 
one patient’s dose being above the licensed maximum daily 
dose of 30mg at discharge and at three months post-
discharge.5 The median discharge B-Z dose, expressed as 
diazepam equivalents, of 10 mg daily is nearly half that 
previously reported12 although the dose range was similar 
to that reported by Summers and Brown.11 Some 
differences will be due to patient characteristics including 
severity and nature of illness or prescriber characteristics 
which can be influenced by local practice and policy20, such 
as z-hypnotic use in preference to benzodiazepine-
hypnotics, e.g. temazepam, due to the potential for misuse 
and drug-related deaths.21,22 
The majority of those prescribed B-Zs had a diagnosis of 
schizophrenia, followed by mood disorders and personality 
disorder, as with other studies10-12, although Summers and 
Brown more commonly reported alcohol dependence as 
the main indication.11 The long-term use of B-Zs in people 
with schizophrenia may be to address suboptimal 
antipsychotic response or an attempt to achieve an 
antipsychotic sparing effect.23 However, the evidence 
supporting such strategies is lacking24, and more 
worryingly, B-Z use is associated with increased mortality 
for people with schizophrenia.9 For those with mood 
disorders, selective serotonin reuptake inhibitors (SSRIs) 
use has been associated with greater longer-term B-Z use, 
and in part may be due to SSRIs exacerbating insomnia and 
agitation, especially at higher doses.25,26 A possible reason 
for long-term B-Z use in personality disorder could be the 
challenging nature of the patients who present with a 
range of behaviours. Nevertheless, B-Zs can provoke 
aggressive behaviour and increase the risk of suicide 
Figure 2. Box plot of total daily doses (expressed as diazepam equivalents) for all patients receiving long-term Benzodiazepines  
or z-hypnotics post-discharge. 
Number of patients receiving long-term Benzodiazepine or z-hypnotics varied during the 12 months. Mann-Whitney U test 
p=0.498, discharge versus quarter 4. 
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amongst people with personality disorder.27 Another 
problem is that concomitant B-Z use can reduce the 
efficacy of some psychological therapies, particularly for 
anxiety.28 Alternatives such as sedating antipsychotics are 
not without their own substantial cardiometabolic risks and 
require more intensive physical health monitoring.29,30 
The main strength of this study is that it uses routine 
patient-level primary care prescribing data for dispensed 
prescriptions containing the CHI number, allowing primary 
and secondary care data to be ‘linked’. This enables 
relatively easy longitudinal assessment of long-term routine 
prescribing, without the demands of significant resource 
implications which previously made this work very 
challenging and prohibitive prior to PIS data being 
available. Another strength was that we did not solely rely 
on the manual collection of prescribing data and the 
inherent problems associated with that type of data 
collection.  
The main limitations, as with other studies, is that we were 
unable to assess concordance and compliance with the 
prescription directions and actual drug use, including 
possible self-medication with non-prescribed B-Zs31,32, as 
well as patient, carer, ward staffing, and prescriber factors 
which are known to be associated with variations in B-Z 
prescribing. The lack of post-discharge information such as: 
if prescribers discussed, attempted or supported patients 
with B-Z reductions; or if patients’ experienced crises which 
did not require admission but did require extra ‘as 
required’ doses which may have inadvertently continued, 
all contribute to potential limitations affecting the depth 
and totality of the analysis. Finally, some may consider 
findings to be limited in their generalisablity; however, this 
study’s findings may be of interest to those working in 
primary and secondary care serving populations with 
similar demographics. 
As already acknowledged, a challenge for practice is 
ensuring good communication between specialist services 
and general practice33,34 to help minimise inappropriate 
long-term B-Z prescribing and avoidable drug-related 
harms. In recent years, pharmacists working within general 
practices have been supporting GPs to review patients 
receiving B-Zs; including those attending mental health 
services, and where appropriate support joined up 
working.35 This study demonstrates the utility of routine 
patient-level PIS prescribing data and ‘linked data’ in 
identifying such prescribing issues within specific patient 
groups at a local level. The use of PIS data will enable 
national, regional, and local services to target resources to 
achieve reductions in inappropriate prescribing of various 
medicines, including psychotropics in line with clinical 
guidance and policies. It can also be used to enable 
clinicians to identify high-priority patients for regular 
medication review in line with national polypharmacy 
guidance supporting the reduction in inappropriate 
medicines and associated avoidable drug risks, as well as 
assessing the impact of regional and national prescribing 
strategies and interventions.36 The ability to ‘link’ PIS 
patient-level data with other datasets at local, regional and 
national levels opens up significant potential for 
pharmacists and non-pharmacist led pharmacovigilance 
and pharmacoepidemolgical studies, as well as evaluating 
changes in routine practice at a local, regional or national 
level. However, patient-level PIS data could also be used to 
support and enable secondary care specialists to review 
and reflect on prescribing as general practitioners and 
practice pharmacists currently do. 
 
CONCLUSIONS 
One in three patients were prescribed B-Zs at discharge 
with 1 in 5 receiving continuous long-term B-Z prescriptions 
12 months post-discharge. For those receiving regular long-
term benzodiazepine and z-hypnotics prescriptions there 
was a small non-statistically significant increase in median 
prescribed dose during the 12 months post-discharge. As 
chronic long-term B-Z prescribing and use still remains an 
issue, future strategies using routine patient-level 
prescribing data may support prescribers to review and 
minimise inappropriate long-term prescribing. 
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